Tetrahydromethotrexate

• CAT Number: I037141
• CAS Number: 4299-28-9
• Molecular Formula: C20H26N8O5
• Molecular Weight: 458.47
• Purity: 98%
• Synonyms: Tetrahydromethotrexate; NSC 526044; NSC-526044; NSC526044
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (2S)-2-[[4-[(2,4-diamino-5,6,7,8-tetrahydropteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
• InChI: InChI=1S/C20H26N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,11,13,24H,6-9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H5,21,22,23,26,27)/t11?,13-/m0/s1
• InChIKey: GLSBTKIRCIEEJO-YUZLPWPTSA-N
• SMILES: CN(CC1CNC2=NC(=NC(=C2N1)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O

Tetrahydromethotrexate（Cat No.:I037141）is a derivative of methotrexate, an antimetabolite commonly used in the treatment of various cancers and autoimmune disorders. It is a more active form of methotrexate, converted by the body into tetrahydrofolate, a cofactor necessary for the synthesis of purines and thymidylates, essential for DNA replication and cell division. Tetrahydromethotrexate is used primarily in cancer therapy, targeting rapidly dividing cells, including those in tumors. It is also investigated in the context of rheumatoid arthritis and other inflammatory conditions. However, its use requires careful monitoring due to potential side effects like bone marrow suppression and liver toxicity.